Full title: An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Details: The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo

 

Specialty: Oncology

Principal Investigator: Dr Gregory Leonard

Study status: Follow up

Identifier: NCT02743494